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This article reviews trends in pediatric solid organ
transplantation over the last decade, as reflected
in OPTN/SRTR data. In 2004, children younger than
18 years made up nearly 3% of the 86 378 candi-
dates for organ transplantation and nearly 7% of the
27 031 organ transplant recipients. Children accounted
for nearly 14% of the 7152 deceased organ donors.
The transplant community recognizes important dif-
ferences between pediatric and adult organ trans-
plant recipients, including different etiologies of or-
gan failure, surgical procedures that are more complex
or technically challenging, effects of development on
the pharmacokinetic properties of common immuno-
suppressants, unique immunological aspects of trans-
plant in the developing immune system and increased
susceptibility to posttransplant complications, partic-
ularly infectious diseases. For these reasons, and be-
Note on sources: The articles in this report are based on the ref-
erence tables in the 2005 OPTN/SRTR Annual Report, which are
not included in this publication. Many relevant data appear in the
figures and tables included here; other tables from the Annual
Report that serve as the basis for this article include the follow-
ing: Tables 1.3, 1.4, 1.5, 1.7, 1.8, 1.10, 1.11a and b, 1.12a and b,
2.1–2.7, 5.1a, 5.3–5.5, 5.9a–c, 5.12a, 5.12c, 5.14, 7.14, 9.1a and
b, 9.3–9.5, 9.7a, 9.9a and b, 9.12a and b, 9.14, 10.1–10.7, 10.9,
10.12, 10.14, 10.15, 11.1b, 11.3–11.5, 11.9, 11.12, 11.14, 12.1–
12.7, 12.9a and b, 12.14, 13.1b, 13.2, 13.4 and 15.3. All of these
tables may be found online at http://www.ustransplant.org.
cause of the impact of end-stage organ failure on
growth and development, the transplant community
has generally provided pediatric candidates with spe-
cial consideration in the allocation of deceased donor
organs. Outcomes following kidney, liver and heart
transplantation in children often rank among the best.
This article emphasizes that the prospects for solid or-
gan transplantation in children, especially those aged
1–10 years are excellent. It also identifies themes war-
ranting further consideration, including organ avail-
ability, adolescent survival and challenges facing pe-
diatric transplant clinical research.
Key words: Deceased donors, graft survival, immuno-
suppression, living donors, organ donation, OPTN, pa-
tient survival, pediatric transplantation, SRTR, waiting
list
Introduction
This article provides important data and analysis regarding
pediatric solid organ transplantation in the United States.
Unless otherwise noted, the statistics in this article are
drawn from the reference tables in the 2005 Organ Pro-
curement and Transplantation Network (OPTN)/Scientific
Registry of Transplant Recipients (SRTR) Annual Report.
We define ‘pediatric’ as a candidate, recipient or donor,
aged 17 years or less. Graft and patient survival are re-
ported as unadjusted survival unless otherwise indicated.
Short-term survival (3 months and 1 year) reflects trans-
plants done from 2002 to 2003; 3-year survival reflects
transplants performed from 2000 to 2003; 5-year survival
reports on transplants performed from 1998 to 2003. A
companion article in this report, ‘Analytical Methods and
Database Design: Implications for Transplant Researchers,
2005’ (1), explains the methods of data collection, orga-
nization and analysis that serve as the basis for this arti-
cle. Additional detail on the methods of analysis employed
herein may be found in the reference tables themselves or
in the technical notes of the OPTN/SRTR Annual Report,
both available online at http://www.ustransplant.org.
Pediatric organ transplant candidates represent a distinct
population in comparison with adult candidates because
of several important differences. These include different
etiologies of organ failure, surgical procedures that are
more complex or technically challenging, effects of de-
velopment on the pharmacokinetic properties of common
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immunosuppressants, unique immunological aspects of
transplant in the developing immune system and increased
susceptibility to posttransplant complications, particularly
infectious diseases. These differences have fostered the
development of independent pediatric transplant programs
or specialized pediatric expertise within transplant pro-
grams that also serve adults. Furthermore, because of the
impact of end-stage organ failure on growth and develop-
ment, the success of pediatric organ transplantation must
also be measured by success in facilitating growth and de-
velopment that is as near normal as possible. Because of
these specific challenges, the transplant community has
generally provided pediatric candidates with special con-
sideration in the allocation of deceased donor organs. In
addition, potential living donors are often more motivated
to donate if the recipient is a child (2).
The frequency of transplant in children ranges from 4% to
15% of that in adults for all organs except small intestine
(which is the least frequently transplanted organ). For this
reason, most centers transplanting pediatric candidates do
not accrue adequate numbers of patients to allow meaning-
ful outcomes analysis or sufficiently powered clinical trials
or research protocols. Indeed, fewer than 25% of centers
reporting pediatric transplants of any organ perform more
than 10 per year (OPTN data, 2005). To overcome these
barriers, the SRTR provides statistical analyses and models
using OPTN/SRTR datasets. These give the OPTN Pediatric
and other committees important information to guide de-
cisions about pediatric organ allocation and outcomes as-
sessment. Moreover, the pediatric transplant community
has developed several collaborative groups or registries
to facilitate analyses not achievable using data collected
by the OPTN. These include the North American Pediatric
Renal Transplant Cooperative Study (NAPRTCS) (3,4), the
Studies of Pediatric Liver Transplantation (SPLIT) (5), the
Pediatric Heart Transplant Study (PHTS) (6), and the Inter-
national Pediatric Lung Transplant Collaborative (IPLTC) (7).
In addition, the Intestinal Transplant Registry covers pedi-
atric intestinal transplantation (8,9).
The Cooperative Clinical Trials in Pediatric Transplantation
(CCTPT), sponsored by the National Institute of Allergy and
Infectious Diseases, continues to fund important trials in
pediatric renal transplantation; this model should be ex-
tended to other pediatric solid organ transplant consortia
to develop strategies to answer questions raised in this
report.
Waiting list
Changes in the waiting list reflect a complex set of inter-
actions. Waiting list additions are driven by the incidence
of end-stage organ failure cases amenable to transplant,
as well as referral patterns and numbers of transplant pro-
grams. Waiting list removals are driven primarily by avail-
ability of suitable organs for transplant and the efficacy of
organ allocation policy. The contribution of each factor is
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Figure 1: Pediatric transplant waiting list at year end, 1995–
2004.
different for each organ. For example, kidney transplanta-
tion is more likely to be influenced by changes in organ
availability and allocation, whereas intestine, a less mature
discipline, may be more influenced by program growth.
Therefore, interpretation of overall changes in the pediatric
waiting list is challenging. Nonetheless, there were 2269
pediatric organ transplant candidates at the end of 2004, re-
versing a 3-year trend of decreases (Figure 1). There were
more candidates in all age groups except 1–5-year-old chil-
dren. Candidates younger than 11 years continue to ac-
count for just over half of pediatric candidates. However,
the increase did not reverse the ongoing decline of pe-
diatric candidates as a percentage of all candidates; chil-
dren currently account for 3% of all transplant candidates.
The trend over the past 10 years has been for steady in-
creases in adult candidates, most dramatically in those over
50 years of age. Although the number of pediatric candi-
dates has increased by about 52% over the decade (2276
from 1491), the total number of pediatric candidates at year
end has not changed substantially since 2001.
In 2004, liver (428) and kidney (620) pediatric candidates
together made up 75% of the active pediatric waiting list
candidates (Figure 2). Over the past decade, the largest per-
centage increase in waiting list activity occurred in intestine
(129%, 62 to 142) and lung (79%, 104 to 186) candidates.
Transplantation and survival
Transplantation: In 2004, there were 1816 pediatric
transplant recipients representing 7% of all recipients. The
relative distribution by age groups has stayed constant over
the decade (Figure 3). However, as with the waiting list, the
combination of a 39% increase in total number of trans-
plants over the decade compared with a 13% increase in
the number of pediatric transplants has led to a decline in
the percentage of pediatric transplants (Figure 4). In liver,
kidney and heart, the percentage of pediatric transplants
is higher than that of waiting list candidates. In contrast,
for lung and intestine the percentage is lower. This likely
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Figure 2: Distribution of active pediatric waiting list candi-
dates by organ, 1995–2004.
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Figure 3: Pediatric transplant recipients, 1995–2004.


















Figure 4: Pediatric and adult transplant recipients, 1995–2004.
reflects a combination of the preference provided for chil-
dren in organ allocation as well as, for liver and kidney, a
higher percentage of living donors for children compared
with adults.
Survival: Although organ-specific graft and patient sur-
vival will be reviewed below, it is worth emphasizing
that the current 3-year graft and patient survival for pe-
diatric recipients are comparable to adult survival for all
but intestine (where interpretation is limited by small
numbers) (SRTR Center-Specific Reports, available at
http://www.ustransplant.org). This observation suggests
that pediatric transplantation has kept pace with im-
provements in graft and patient survival for transplan-
tation as a whole seen over the past decade. A few
specific pediatric age groups deserve comment. Pa-
tients younger than 11 years have the best unadjusted
5-year graft survival rates among all types of renal trans-
plantation. In addition, children aged 6–10 years have the
best outcomes among liver transplant recipients. In con-
trast, infants less than 1 year and adolescents aged 11–17
years tend to have among the lowest unadjusted 5-year
graft survival rates across all organs. However, the majority
of 5-year unadjusted graft survival rates for these groups in
each organ improved compared with previous years. Given
these observations, being in the pediatric age group should
not be considered a risk factor for poor outcomes following
transplantation.
Pediatric organ donors
In 2004, there were 975 pediatric deceased organ donors.
Although this represents a 10% increase compared with
2003, there still has been a 19% decrease in pediatric
deceased organ donors over the past decade. In con-
trast, the 11% increase in adult deceased donors over
the past year yields a net 48% increase for the past
decade. Thus, pediatric donors continue to make up a de-
clining percentage (14%) of all organ donors. Nonethe-
less, as the majority of pediatric donors are at least 11
years old, and because only 7% of deceased donor re-
cipients are pediatric, it is clear that a considerable num-
ber of adults continue to be recipients of pediatric de-
ceased donor organs. Pediatric donors are more likely to
donate each type of organ than adult donors. For exam-
ple, 47% of pediatric donors provided a heart, compared
with 26% of adult donors. The average number of or-
gans recovered from a pediatric donor was 3.0 compared
with 2.5 for adult deceased donors. These data are con-
sistent with the report that pediatric deceased donors
are more likely than adults to donate each type of organ
(10).
The past year has shown improvement for pediatric trans-
plantation in terms of waiting list numbers, numbers of
transplants and pediatric organ donors. Nonetheless, chal-
lenges remain. Despite the recent increase, the number of
pediatric organ donors has declined over the past decade.
And although there has been some improvement, mortal-
ity for infants aged less than 1 year and the adolescent
age groups remains a concern. These issues and other
organ-specific trends are detailed below. Finally, recent
changes in organ allocation policy and the use, in chil-
dren, of organs from donation after cardiac death (DCD) are
reviewed.
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Kidney Transplantation
Although children with end-stage renal disease have the
life-sustaining option of dialysis, because kidney transplan-
tation affords superior quality of life, it is considered the
optimal modality for these children.
The most recent report (4) from the NAPRTCS database
shows steady improvement in the 1-year deceased donor
and living donor graft survival rate since its inception in
1987. For the initial cohort period 1987–1990, the living
donor and deceased donor 1-year graft survival rates were
89% and 75%, respectively, which improved to 96% and
93%, respectively, for the most recent (1999–2004) period.
This improvement paralleled the decreased incidence of
acute rejection episodes. For 1987–1990, the living donor
and deceased donor 1-year probability of an acute rejection
episode was 54% and 69%, respectively, compared with
16% and 21% for 2003–2004. The long-term (7 year) graft
survival rate has shown a concomitant increase. For the
period 1987–1994, the living donor and deceased donor
7-year graft survival rate was 72% and 55%, respectively,
which improved to 76% and 65% for the most recent pe-
riod (1995–2004). Chronic allograft nephropathy is currently
the most frequent (34%) cause of allograft failure in the
NAPRTCS database.
The two most recent reports of the SRTR emphasized the
improvement in patient and graft survival rates in pedi-
atric recipients (10,11) dispelling previous concerns that
the youngest recipients were at higher risk for graft fail-
ure. In actuality, recipients aged less than 11 years had the
highest 1- and 5-year graft survival rates compared with all
other age groups. A cautionary note was identified in these
two reports with respect to the adolescent recipient. The
long-term (5 year) graft survival rate for deceased donor
and living donor recipients for the 11–17-year-old recipi-
ent was inferior to all other age groups except those over
65 years.
Since the number of pediatric recipients transplanted an-
nually is limited and even at a robust pediatric center rarely
exceeds 30 transplants, it is imperative that national and
international databases exist to identify research efforts to
improve outcomes of pediatric recipients.
Waiting list
In the pediatric population, there has been a modest in-
crease during the past decade of active candidates on the
kidney active waiting list, from 470 in 1995 to 620 in 2004
(Figure 5). However, as a percentage of the total waiting
list, which nearly doubled during the past decade, the pe-
diatric population has declined from 1.8% in 1995 to 1.4%
in 2004.
The only substantive increase in the pediatric waiting list
during the past decade occurred in the adolescent age
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Figure 5: Pediatric kidney transplant waiting list at year end,
1995–2004.
group (11–17 years), with an increment of 128 patients
compared with an increment of nine in the 1–5 year and
10 in the 6–10-year age group. From 2003 to 2004, the
number of patients in the 1–5, 6–10 and 11–17–year-old
age groups identified on the kidney waiting list increased
by 18, 10 and 32, respectively. As the incidence of renal
transplant in the pediatric population has not changed ap-
preciably and the median time to transplant for the 11–17-
year-old age group has increased from 276 to 450 days,
this increase may reflect increased competition for organs
from adults.
The mortality rate for children on the kidney waiting list
is exceedingly low compared with other age groups (Fig-
ure 6). During the past decade, the total number of patient
deaths on the kidney waiting list increased from 1625 in
1995 to 4030 in 2004. However, although there were mod-
est fluctuations annually, the deaths in the pediatric popu-
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Source: 2005 OPTN/SRTR Annual Report, Table 5.3.
Figure 6: Annual death rates per 1000 patient-years at risk by
age, kidney waiting list, 1995–2004.
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despite a concurrent increase in the pediatric waiting list
population.
However, the mortality rate for infants, children and ado-
lescents undergoing dialysis is not inconsequential. One-
and two-year patient survival for 853 patients enrolled in
the NAPRTCS Dialysis Registry from 2001 to 2004 was
98% and 93%, respectively, with increasing mortality in
the younger age groups (4). Recent changes to the pedi-
atric kidney allocation policy, detailed later in this article,
preferentially allocate kidneys from deceased donors less
than 35 years of age to children. It is expected that this
policy will stabilize or reverse waiting list increments seen
recently and reduce pediatric mortality on the kidney wait-
ing list.
Transplantation and survival
Transplantation: In 2004, 765 children received a kid-
ney transplant (384 kidneys from living donors, 378 from
deceased donors that were not expanded criteria donors
(ECD) and three from ECD deceased donors). This total has
minimally increased (8%) from the 719 kidney transplants
(389 living donors, 322 deceased donor/non-ECD and eight
deceased donor/ECD) performed in children in 1995. How-
ever, in contrast to the last two SRTR reports (10,11) where
living donor transplants contributed to the increment in
pediatric transplants, the increment has abated in 2004
(Figure 7). This is especially notable in the 6–10 year and
11–17-year age groups; these numbers decreased from 93
and 252, respectively, in 2002 to 67 and 210, in 2004.
The number of children receiving a deceased donor kid-
ney (almost entirely non-ECD) has increased modestly
(15%) during the past decade, from 330 in 1995 to 381
in 2004 (Figure 8) The number of deceased donor trans-
plants in adolescents has increased modestly, while the
number performed in the younger children has remained
relatively constant. Across both the pediatric and adult pop-
ulation, the total number of deceased donor/non-ECD kid-
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Source: 2005 OPTN/SRTR Annual Report, Table 5.4a.
Figure 8: Pediatric transplant recipients of non-ECD deceased
donor kidneys, by age, 1995–2004.
neys transplanted showed a gradual increase during the
past decade, from 6679 in 1995 to 7270 in 2003; however,
there was a substantial (9%) increase to 7915 in 2004.
Survival: Short-term graft survival for pediatric recip-
ients of both deceased donor and living donor kidneys
has improved over the past decade; the difference in the
1-year graft survival rate between the two donor categories
has diminished markedly (4). The 1-year unadjusted graft
survival rate of deceased donor/non-ECD kidneys in 2004
was 91% for all recipients and ranged from 88% to 92%
for pediatric recipients (Figure 9). The 1-year unadjusted
graft survival rate for all living donors in 2004 was 95%
and ranged from 96% to 100% for pediatric recipients
(9). The superb short-term graft survival rate probably re-
flects substantive advances in clinical management, as
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Source: 2005 OPTN/SRTR Annual Report, Table 5.9a and 5.9c.
Figure 9: Unadjusted 1- and 5-year graft survival of living and
deceased donor non-ECD kidney transplants by recipient age.
1136 American Journal of Transplantation 2006; 6 (Part 2): 1132–1152
Pediatric Transplantation, 1995–2004






















Living Donor Deceased Donor non-ECD
Figure 10: Unadjusted 5-year patient survival of living and
deceased donor non-ECD kidney transplants by recipient age.
Long-term graft survival rates in pediatric recipients con-
tinue to improve; however, annual attrition primarily from
chronic allograft nephropathy continues unabated with the
current clinical management. The decreasing disparity in
short-term graft survival rates between deceased donor
and living donor kidneys is not perpetuated for long-term
rates. The 5-year unadjusted graft survival rate in 2004 for
1–5 year, 6–10 year, and 11–17-year age groups from de-
ceased donor/non-ECD and living donors were 75%, 73%,
65%, and 91%, 87% and 79%, respectively. Numbers for
the entire kidney waiting list in 2004 are similar: graft sur-
vival was 69% for deceased donor organs versus 80% for
living donor kidneys. The limited number of infants under
1 year who received grafts from a deceased donor (n = 1)
or living donor (n = 25) obviated the ability to include this
age group in the analysis. However, the excellent long-term
survival of the youngest recipients (1–5 years) of both de-
ceased donor and living donor grafts as reported previously
(10,11) justifies continued preferential allocation for the pe-
diatric age recipient. Most disturbing is the continued poor
long-term graft survival rates in the adolescent recipient,
which also has been identified previously (10,11). The etiol-
ogy of this phenomenon is speculative, with nonadherence
a potential major contributor (12).
As expected, the unadjusted survival of pediatric recipients
receiving either a deceased donor/non-ECD or living donor
kidney transplant is excellent and substantively better than
the adult age groups (Figure 10). The unadjusted 5-year pa-
tient survival rates in 2004 for all deceased donor/non-ECD
and living donor recipients were 83% and 90%, respec-
tively. Pediatric recipients have better long-term survival:
among 1–5-year-old children, these rates were 92% and
95%, respectively, 95% and 97% among 6–10-year olds,
and 97% and 98% among 11–17-year olds.
Organ donation
The number of deceased donor kidneys from pediatric
donors has continued to decrease during the past decade,
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Figure 11: Deceased kidney donors by age, 1995–2004.
both in absolute numbers and as a percentage of the to-
tal number transplanted (Figure 11). Between 1995 and
2004, the total number of deceased kidney donors in-
creased from 5003 to 6327; pediatric deceased kidney
donors decreased from 1083 to 867. In 1995, 22% of
the deceased donors were pediatric; in 2004 this num-
ber decreased to 14%. Some of the decrease could be
attributable to the reluctance to transplant kidneys from
young pediatric donors into young pediatric recipients be-
cause of poorer outcomes primarily attributable to an in-
creased incidence of vascular thrombosis (13). However,
in 1995, 14% of deceased kidney donors were aged 11–
17 years; in 2004, this decreased to 8%. Multiple factors
probably contributed to this reduction. An assessment of
the factors is indicated, especially because recent data
show that en bloc transplantation of kidneys from young
pediatric donors into adult recipients is efficacious (14).
Although the graft survival rate of kidneys transplanted into
pediatric recipients has improved during the past decade,
nonadherence in adolescents (12) and chronic allograft
nephropathy (4) must be addressed if long-term pediatric
kidney allograft survival rates are to continue to improve in
infants, children and adolescents.
Liver Transplantation
Pediatric liver transplant recipients differ from their adult
counterparts with respect to the relative distribution of
etiologies of liver disease and indication for transplanta-
tion. Additionally, the impact of end-stage liver disease on
growth and development leads to a distinct morbidity in
this population. In addition to ongoing pediatric analyses
by the SRTR, the SPLIT registry provides a rich source of
pre- and posttransplant outcomes in this population (5,15).
The SPLIT consortium has recently secured NIH funding,
which should further its abilities to ask important questions
in this population. Other NIH initiatives, including the Bil-
iary Atresia Research Consortium (BARC) and Cholestatic
































Source: 2005 OPTN/SRTR Annual Report, Table 9.1a.
Figure 12: Active pediatric patients on the liver transplant
waiting list, 1995–2004.
Liver Disease Consortium, will add to our understanding of
liver disease in the pediatric population.
Waiting list
At the end of 2004, 428 of the 12 744 candidates ac-
tively awaiting liver transplantation were pediatric patients.
Of these children, 61 were less than 1 year of age, 154
were aged 1–5 years, 88 were aged 6–11 years and 125
were 11–17 years of age. The relative distribution of these
age groups has not changed noticeably over the decade
(Figure 12).
Over the last decade, the large increase in the numbers
of adult candidates awaiting liver transplantation has led
to a decline in the overall proportion of pediatric candi-
dates represented on the waiting list, from 9% in 1995
to 3% in 2004. The absolute number of children await-
ing transplantation at year end grew steadily from 1995
to 2001 (Figure 12). However, over the last 3 years, there
has been an appreciable decline in the number of pedi-
atric candidates awaiting transplantation, a decrease seen,
too, in adult candidates. Absent any major change in the
incidence or management of end-stage liver disease, or
changes in indications for transplantation or numbers of
transplants performed, it is likely this decrease reflects a
change in listing practices attributable to the implemen-
tation of the Model for End-stage Liver Disease (MELD)
and Pediatric End-stage Liver Disease (PELD) scores in
2002. Because these allocation strategies emphasize dis-
ease severity over waiting time, it is no longer necessary
to list candidates for the purpose of accruing priority for
organ allocation.
In addition to 428 active candidates, another 409 chil-
dren were listed but inactive at year end. The relative
percentage of active patients compared with the total
listed is lower in the pediatric population (51%) com-











































Source: 2005 OPTN/SRTR Annual Report, Table 9.3.
Figure 13: Annual death rate per 1000 patient-years at risk for
pediatric patients on liver waiting list, 1995–2004.
In 2004, 80 pediatric candidates died while on the waiting
list. Of note, 36 of these deaths were in patients listed for
multiorgan transplants, including 29 children listed for liver-
intestine transplantation (SRTR analysis, August 2005). The
death rate in children listed for multiorgan transplant is dis-
proportionately high compared with children listed for liver
alone. Over the last 10 years, the death rate for patients
awaiting liver transplantation across all pediatric and adult
ranges has declined, with the notable exception of chil-
dren less than 1 year of age (Figure 13). These infants
still have the highest death rate of any age range, with
a rate of 591 per 1000 patient-years at risk. Children aged
6–10 years and 11–17 years have the lowest death rates
of any age group (23 and 49 per 1000 patient-years at
risk, respectively), while children in the 1–5-year age group
had an intermediate rate of 132 per 1000 patient-years at
risk.
Since implementation in 2002, it has been possible to strat-
ify patient outcomes based on MELD or PELD scores.
When waiting list mortality rates are analyzed by PELD
score, candidates with a PELD <11 had a death rate of
26, while those with a PELD of 11–20, 21–30 and >30 had
rates of 225, 308 and 224 per 1000 patient-years at risk,
respectively. While the utility of direct comparison of PELD
to MELD is limited, it is worthwhile to note that adult can-
didates with a MELD of 11–20 had a death rate of 137;
this rate dramatically increases with higher MELD scores.
The observed relative plateau in death rates with higher
PELD scores is not in itself an indication that PELD does
not reflect disease severity. Rather, this plateau reflects, at
least in part, a higher rate of transplantation in children with
higher PELD scores which limits waiting list deaths. Addi-
tionally, a substantial portion of children with high PELD
scores are changed to Status 1, which may also act to
limit the deaths observed at higher PELD scores. The im-
pact of the recent changes in allocation policy limiting the
practice of upgrading children to Status 1 remains to be
determined.
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Source: 2005 OPTN/SRTR Annual Report, Tables 9.4a and 9.4b.
Figure 14: Pediatric recipients of deceased and living donor
liver transplants, 1995–2004.
Transplantation and survival
Transplantation: In 2004, there were 529 deceased
donor liver transplants into pediatric recipients, an increase
of 51 more transplants compared with 2003 (Figure 14). Pe-
diatric recipients accounted for 9% of the 5845 deceased
donor liver transplants performed in 2004. While the total
number of deceased donor transplants performed across
all ages has dramatically increased over the decade, from
3880 in 1995 to 5845 in 2004 (a 51% increase), the number
of pediatric deceased donor liver transplants has increased
modestly from 452 to 529 (17%).
Living donor liver transplantation was first performed in
1989. In 2004, living donation accounted for 50 transplants
in the pediatric population (Figure 14). Notably, this repre-
sents the smallest number of living donor liver transplants
performed in children over the last decade and is a marked
decrease from a peak of 117 such transplants in 2000.
Of the living donor liver transplants performed in 2004, 43
were in children 5 years of age and younger, while the re-
maining seven were performed in children between ages
11 and 17 years.
It is interesting to reflect on the practice pattern of living
donor liver transplantation over the last 10 years. In 1995,
all 54 living donor liver transplants were performed in pedi-
atric recipients. In 2004, there were 50 living donor trans-
plants performed in children and 273 such transplants in
adults. The number of adult-to-adult living donor liver trans-
plants has remained relatively stable for the last 3 years
(range: 253–289), but it is substantially less than the 408
such transplants performed in 2001.
While the relative contributions of deceased donor and liv-
ing donor transplantation have changed over the years,
the total number of pediatric liver transplants performed
has been relatively stable (Figure 14). The incidence of
transplantation, expressed as the number of transplants
per one million population, has also stayed relatively con-
stant across the pediatric population for the last 10 years,
Table 1: PELD score at transplant, 2004
Deceased donor Living donor
PELD <11 87 10
PELD 11–20 53 7
PELD 21–30 40 3
PELD >30 10 1
Total PELD 190 21
Total non-PELD 339 29
Source: 2005 OPTN/SRTR Annual Report, Tables 9.4a and 9.4b.
but has increased 1.5- to 2-fold in adults older than
50 years. For pediatric recipients, incidence of transplan-
tation is highest in infants less than 1 year (39.7 per
million), followed by the 1–5-year age group (10.39 per
million). Children in the 6–10 year range have the low-
est incidence of transplant of any age group at 3.78 per
million.
For pediatric recipients allocated a deceased donor liver by
their PELD score, the majority had a score ≤20 (Table 1)
and many had a PELD <11. A similar trend is noted for
recipients of living donors. The PELD score was only used
in 190 of the 529 deceased donor transplants (36%). The
majority of the other such transplants were performed in
children with chronic liver disease, either awarded a PELD
score based on exception or made a Status 1. There ap-
pears to be marked regional variation of the use of such
mechanisms (16–18). Steps being taken to make listing
practices less subjective include establishing detailed Sta-
tus 1 criteria for pediatric patients with chronic liver disease
and consideration of the role of regional review boards in
the exception process.
Survival: Annual death rates in the first year following
deceased donor liver transplantation across the pediatric
age ranges have generally improved over the last decade
(Figure 15). This improvement has been most marked
among infants aged less than 1 year. Pediatric recipients
currently have lower death rates in the first year follow-
ing transplantation compared with adult recipients. When
these death rates are examined as a function of PELD score
at time of transplant, in 2003 children with a PELD <11 had
a death rate of 68.1 per 1000 patient-years at risk. Children
with a PELD of 11–20 at time of transplant had a rate of
70.9 per 1000 patient-years at risk, while the rate for those
with a PELD of 21–30 was 161.1.
Children aged 6–10 years and 11–17 years who receive a
deceased donor transplant have the best 1-year graft sur-
vival across all age ranges, but the poorest graft survival
following the living donor transplantation (Figure 16). For
infants less than 1 year, living donor graft survival exceeds
that observed from deceased donors. Unadjusted patient
survival at 1 year following deceased donor liver transplan-
tation is excellent across all ages (Figure 16), though sur-
vival following living donor liver transplantation in children















































Source: 2005 OPTN/SRTR Annual Report, Table 9.7a.
Figure 15: Annual death rate per 1000 patient-years at risk
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Source: 2005 OPTN/SRTR Annual Report, Tables 9.9a, 9.9b, 9.12a and 9.12b
Figure 16: Unadjusted 1-year graft and patient survival of de-
ceased donor and living donor liver transplants by recipient
age.
1 year of age and older is below that observed for deceased
donors. Patient survival at 5 years after deceased donor
liver transplantation in the pediatric population ranges from
79% to 87%, which exceeds the survival observed in
adult recipients. The reason for notably poorer outcomes
following living donor liver transplantation in children 6–
17 years of age is unknown, though technical factors in-
cluding graft to recipient volume, severity of illness and
etiology of liver failure may all contribute.
In assessing the decision when to transplant a child, an ap-
preciation of the real risk of posttransplant mortality is vital.
Recently, Merion and colleagues demonstrated that adult
candidates with a MELD <15 faced a higher risk of mor-
tality in the first year after transplantation compared with
remaining on the waiting list (19). For pediatric patients,
the data are less clear. While children with end-stage liver
disease face additional risks of morbidity related to growth
and development, it is intuitive that there is some level of
liver disease for which the risk of transplantation exceeds
the risk of remaining on the waiting list. It remains unclear,
however, where that level of disease is (20). The challenge
for the pediatric community is to better understand these
specific risks and benefits in order to make the optimal
decisions.
Intestinal Transplantation
The worldwide experience in intestinal transplantation now
exceeds 1000 patients (21), and its place as accepted ther-
apy for patients with intestinal failure and life-threatening
complications in the United States was established in 2001
when the federal government approved Medicare fund-
ing for this procedure. Previous SRTR reports and single-
center publications have documented improving outcomes
(10,11,22,23). Increasing numbers of centers have been
establishing intestinal transplant programs. The interna-
tional Intestine Transplantation Society has been estab-
lished in the last 2 years and this year, the 9th International
Small Bowel Transplant Symposium was held. Despite the
growing maturity of intestine transplantation, problems still
relate to the difficulty in obtaining suitable composite al-
lografts for patients with intestinal failure and associated
end-stage liver disease. This is reflected in high waiting
list mortality rates for intestinal transplant candidates. The
postoperative care is intensive and complex, and infection
due to over-immunosuppression and rejection due to inad-
equate immunosuppression yield limited short-term out-
comes. This has resulted historically in graft and patient
survivals that have been less successful than those seen
for liver, kidney or heart transplantation.
Waiting list
The intestinal waiting list has two active categories, ur-
gent and nonurgent, and within these categories, organs
are allocated based on waiting time. Allocation from this
list is primarily to candidates listed for isolated intestine
transplantation, though it is acceptable for an organ pro-
curement organization to allocate a combined liver-small
intestine allograft from this list, provided there are no Sta-
tus 1 liver patients waiting in that region (24, OPTN Policy
3.11.4). In practice, the majority of combined liver and small
intestine allografts are allocated according to the patients’
MELD or PELD score, i.e. according to liver allocation pol-
icy. It has long been recognized that waiting list mortality
is high, particularly for small infants waiting for liver-small
intestine transplantation and that waiting list mortality is
higher for any given PELD score when compared with iso-
lated liver candidates. Based on the limited data available
shortly after the introduction of PELD, the SRTR calculated
the size of the difference in mortality rate between the
liver-only patients and liver-intestine candidates. Based on
these estimates, OPTN allocation policy was changed to in-
clude an additional 10% mortality risk above that predicted
by their calculated PELD or MELD score (24, OPTN Pol-
icy 3.6.4.7). The same SRTR analysis demonstrated that
there was no interaction between waiting list mortality for
liver-intestine candidates and PELD, suggesting that PELD



























Source: SRTR Analysis, May 2005 and 2005 OPTN/SRTR Annual Report, 
Table 1.3. 
Figure 17: Differential growth of the waiting list, intestine and
liver-intestine, 1995–2004.
was equally predictive for increasing waiting list mortal-
ity for both liver-alone candidates and liver intestine candi-
dates, but, for the latter group, at a higher level (25). Up-
dated analysis with an additional 2 years of data suggest,
at least for children, that this increased mortality risk on
the waiting list may be still greater than the 10% presently
allowed. These findings have yet to be discussed in the
appropriate OPTN committees; it would be premature to
predict whether this latest analysis will lead to further al-
teration in allocation policy.
Examining the number of candidates on the waiting list re-
veals increasing demand for intestinal transplantation over
the last 10 years (Figure 17). At the end of 1995, 82 can-
didates were listed for intestine transplant; in 2004, this
figure was 196. The waiting list for isolated intestinal trans-
plantation (from 22 patients in 1995 to 105 in 2004) has
grown more rapidly than listings for combined liver and
intestine transplantation (from 60 in 1995 to 91 in 2004)
and may be related to earlier referral of patients for in-
testine transplant (SRTR analysis, May 2005). Of these
196 candidates, 142 were less than 18 years old and ap-
proximately 49% of the listed candidates were younger
than 6 years. The ratio of adults to children does not ap-
pear to be changing over time. In terms of race/ethnicity,
the majority of candidates are white and non-Hispanic,
although the proportion of whites has fallen over the
10-year period, from 75% to less than 60% of the intestine
list. The proportion of African American candidates has not
changed noticeably. Hispanics have increased from 7% in
1995 to 17% in 2004. Greater demand can also be seen in
the number of new registrants to the intestine list, which
increased from 91 in 1995 to 250 in 2004.
In 2004, the median time to transplant for all intestine reg-
istrants was 238 days, the lowest level in 10 years (Fig-
ure 18). Still, the longest waits are those of infants aged
less than 1 year. The most dramatic reduction is seen in


































Source: SRTR Analysis, May 2005 and 2005 OPTN/SRTR Annual Report, 
Table 1.5.
Figure 18: Median time to transplant for intestine and liver-
intestine registrations, 1999–2004.
whose median waiting time is 163 days (SRTR analysis,
May 2005). This finding may result from changes in liver
allocation policy as it relates to candidates for combined
liver and intestine transplant. However, noticeable reduc-
tions in waiting list mortality in this group are not being
seen.
The annual death rate on the intestine waiting list is 306 per
1000 patient-years at risk for all intestinal candidates, which
is by far the highest for any solid organ transplant group
and has not shown any substantial changes in 10 years. To
put this in perspective, the annual death rate for intestinal
transplant recipients is twice that of the next highest risk
group (combined heart and lung candidates). Infants less
than 1-year old have consistently high death rates, about
double those seen in the intestinal group as a whole. High
death rates in the youngest children probably relate to the
combination of a number of factors, including severity and
rapid progression of liver disease, higher incidence of sep-
sis, and the inherent difficulty in obtaining size-matched
allografts. Candidates 6–17 years old have considerably
lower waiting list death rates; this probably reflects that
these children do not have advanced liver disease and are
more likely to be listed for isolated intestinal transplant. Of
the patients who died awaiting intestine transplantation
over the period from 1995 to 2004, 92% of deaths were
in patients also listed for a liver transplant (SRTR analysis,
May 2004). This is not unexpected; even if a candidate is
initially listed for intestine transplant only, as their disease
progresses they also are likely to become candidates for a
liver transplant. These data, however, show that patients
with intestinal failure are not dying in large numbers prior
to transplant in the absence of advanced liver disease.
Previous SRTR annual reports have examined the number
of potential donors that ultimately become small intestine
donors. There were 7152 deceased donors in 2004; 297
were less than 6 years and 97 were younger than 1 year.
But of these, only 87 and 43 of those younger than 6 years
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and 1 year, respectively, became small intestine donors. If
we look at the same donors in terms of livers procured, 262
donors younger than 6 years and 86 donors younger than
1 year became liver donors. Perhaps infant intestinal can-
didates should receive preferential access to these donor
organs, given that liver-only candidates have a number of
other options, including reduced-size split and living-related
livers.
Transplantation and survival
Transplantation: In 2004, 152 intestinal transplants
were carried out in 17 U.S. centers, compared with 46
transplants in 10 centers in 1995. Fifty-two patients re-
ceived isolated intestinal transplants and 100 received in-
testinal transplants in combination with other abdominal
organs; all but five included a liver. Children made up 61%
of recipients; 50% were children in the 0–5-year age group.
Similarly, in the last 10 years, 61% have been in the pedi-
atric age group. The incidence of intestinal transplantation
remains low but increased in 2004 to 0.52 transplants per
million population compared with 0.18 transplants per mil-
lion in 1995. The highest rates were among the youngest
children, with an incidence of 5.71 per million in infants
aged less than 1 year and 2.67 per million in children aged
1–5 years. The incidence in the 6–17-year age group was
essentially unchanged over the 10-year period. These fig-
ures can be compared with the incidence of kidney trans-
plantation of 54 per million and liver transplantation of 21
per million population. The incidence of intestine trans-
plantation appears to be equal between racial and ethnic
groups, and by sex. The low incidence of intestinal trans-
plantation is, in part, due to the relative rarity of intesti-
nal failure compared with renal or liver disease. But the
contribution of lack of access to organs and experienced
transplant programs cannot be estimated.
Survival: Graft survival following intestine transplanta-
tion has improved over the 10-year period, with 1-year
unadjusted graft survival at 77% in 2003 compared with
59% in 1994; the most notable improvements occurred
over the last 4 years (Figure 19). This period of time has
seen increased use of antibody induction therapies includ-
ing IL2 receptor inhibitors (basiliximab or daclizumab), rab-
bit antithymocyte globulin and alemtuzumab. Unadjusted
graft survival rates for the most recent cohorts are 87% at
3 months, 73% at 1 year, 52% at 3 years and 43% at 5
years. Patient survival also has shown improvement; the
annual death rate per 1000 patient-years at risk for recipi-
ents in the first year after intestinal transplants has fallen
over the last 5 years from 515 in 1999 to 208 in 2003. Un-
adjusted patient survival at 3 months, 1 year, 3 years and
5 years, now stands at 90%, 79%, 61% and 52%, respec-
tively. Death rates are highest for the youngest children,
ranging from 1222 per 1000 patient-years at risk in 2000 to
331 in 2003. Conversely, the lowest death rates were ob-























Source: SRTR Analysis, May 2005 and 2005 OPTN/SRTR Annual Report, 
Table 1.11b.
Figure 19: One-year unadjusted graft survival of deceased
donor intestine and liver-intestine transplants, 1994–2003.
1000 patient-years at risk in 2003. These differences most
likely relate to the number of isolated intestinal transplants
in relatively healthy teenagers, whereas the sicker infants
require combined intestine and liver transplants.
An update from the Intestinal Transplant Registry was re-
cently published (9). Up until May 2003, the total world
experience in human intestine transplantation amounted
to 989 transplants in 923 patients. Furthermore, 61% of
patients were less than 18 years of age and 75% of trans-
plants were done in the United States. In the most re-
cent cohort from the database (1998–2003), 1-year graft
survival was 65%, with patient survival at 77% for iso-
lated intestine transplantation; graft and patient survival for
liver and intestine recipients were 59% and 60%, respec-
tively. The OPTN/SRTR data for 2004 suggest still further
improvements in survival following intestine transplanta-
tion. The reasons for improved outcomes are multifactorial
but include greater experience and refinement of surgical
techniques, patient selection and changes in immunosup-
pressive regimens (including increased popularity of anti-
body induction regimens). Changes have also been imple-
mented in the management and surveillance of infectious
complications, such as routine surveillance for Epstein-Barr
virus and treatment of PTLD.
Short-term survival rates have been improving and may
now be approaching rates seen for other solid organ trans-
plant groups. Attention is currently being given to issues
related to long-term survival, quality of life and growth and
development. Immunosuppressive minimization is being
approached from a number of angles to reduce compli-
cations associated with long-term use and side effects
of immunosuppressant therapies. Antilymphocyte anti-
body induction regimens without maintenance corticos-
teroids have been introduced in a number of centers with
promising early results (9,23,26) The priority for intes-
tine transplant candidates is to examine whether further
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changes in organ allocation policy can reduce high waiting
list death rates, particularly for those awaiting combined
liver and intestinal transplantation.
Heart Transplantation
Compared with adults, pediatric heart transplantation is
characterized by the striking number of infants and chil-
dren with congenital cardiac anomalies. Challenges include
higher waiting list mortality (due to limited access to ven-
tricular assist devices), coronary vasculopathy and long-
term immunosuppression complications.
Waiting list
The number of pediatric patients awaiting heart transplan-
tation has been relatively steady over the past 5 years; the
number awaiting transplantation at the end of 2004 was
256, while the 5-year average is 243. Children consistently
account for 5–7% of all of those awaiting heart transplants.
As in prior years, the largest age group among children
waiting for a heart transplant is aged 1–5 years, followed
by adolescents aged 11–17 years. However, for a single 1-
year age group, infants (0–1 year) make up by far the largest
group of candidates. Infants represented 168 of 459 (37%)
of new pediatric registrations in 2004 (Figure 20).
The diagnoses leading to listing for transplantation vary by
age. For infant candidates, the indication for placement on
the waiting list is a congenital heart anomaly in over two-
thirds of patients (27). In older children and adolescents,
cardiomyopathy is the leading indication for transplanta-
tion; the dilated form is most common. Congenital cardiac
anomalies do, however, continue to account for a sub-
stantial minority of transplants even in older age groups.
This observation is important because complex cardiac
anatomy, in addition to small size, precludes the use of
ventricular assist devices for many children with end-stage
cardiac failure. Difficulty supporting these young patients
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Figure 20: New pediatric registrants on the heart waiting list
by age, 1995–2004.
with complex congenital heart disease undoubtedly con-
tributes to their high waiting list mortality.
Although children in all age groups have substantially
shorter waiting times (median waiting times range from
57 to 154 days) than do adults, they have a substantially
greater risk of death while on the waiting list. The an-
nual waiting list death rate (expressed per 1000 patient-
years at risk) is higher in all pediatric age groups com-
pared with all adult candidates less than 65 years. The
highest death rate is among infants aged less than 1
year. An informative way to view pretransplant outcomes
is with competing outcomes analysis (28). This approach
provides a time-related prediction of simultaneous mu-
tually exclusive events (e.g. death while waiting, trans-
plantation, still waiting, etc.). Analysis of all 2375 patients
listed for transplantation from January 1, 1993 through
December 31, 2003 in the PHTS, a North American multi-
institutional study of outcomes after listing for heart trans-
plant, demonstrates that the proportion of patients trans-
planted increases over time to 68% by 1 year after listing,
while the proportion who die on the waiting list increases
to a maximum of 17% by 1 year (29). The same data set
shows evidence for a decrease in waiting list mortality in
pediatric heart transplant candidates over the last 5 years
compared with earlier eras. It should be noted that most
deaths on the waiting list occurred in Status 1A patients
(most urgent status), with a very low 1-year waiting list mor-
tality for Status 2 patients (approximately 5%). These data
suggest that the OPTN urgency status system appears to
be meeting its primary objective of prioritizing those pa-
tients most likely to die soon without transplantation.
Transplantation and survival
Transplantation: Over the past 10 years, children have
accounted for approximately 12% of all heart transplant re-
cipients and the number of transplants has remained sta-
ble at around 250–290 per year (Figure 21). Prior to 1998,
infants were generally the largest pediatric group receiv-
ing transplants on an annual basis; since then, adolescents
constituted the largest group. This change likely reflects
widespread adoption of staged reconstruction (Norwood
procedure) for initial palliation of hypoplastic left heart syn-
drome (HLHS) in most centers. Because of the scarcity
of donor organs and consequent long waiting list times
for newborns, only a few centers continue to offer trans-
plantation as primary therapy for newborns with HLHS.
Despite these trends, the rate of transplantation per 1 mil-
lion population remains higher for infants than for any other
age group, except adults between 50 and 64 years, among
whom it is slightly higher. The high rate of transplantation in
these very young children reflects the high incidence of se-
vere symptomatic congenital heart disease in the first year
of life and the relatively high incidence of cardiomyopathy
in this age group (30,31). Currently, approximately 60–80
heart transplants are performed each year in the United
States in infants.
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Source: 2005 OPTN/SRTR Annual Report, Tables 11.3, 11.4, and 15.3.
Figure 21: New pediatric heart waiting list registrants, deaths
on the waiting list, and transplants, 1995–2004.
Survival: Retransplantation is rare in the early years af-
ter heart transplantation; therefore, graft survival rates and
patient survival are very similar (Figure 22). One-year unad-
justed patient survival rates in childhood are similar across
all ages, with only slightly lower survival in infants com-
pared with older children (1-year unadjusted patient sur-
vival of 85% in infants vs. 89% in the 11–17-year age
group). These results are also comparable with those in
adults less than 65 years old. However, at 5 years, infant
survival exceeds that of all other age groups including most
adult groups (5-year survival for infant recipients is 75% vs.
70% for recipients in the 11–17-year age group.) This likely
reflects the higher perioperative mortality associated with
transplantation for congenital heart disease in young in-
fants, but a lower late mortality in the same population. The
latter finding is most likely because of a lower incidence
of posttransplant coronary artery disease in young trans-
plant recipients (6). Regardless of age at transplant, those
transplanted for congenital heart disease have worse pa-
tient survival (27,30). In contrast to adults, there is evidence
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Source: 2005 OPTN/SRTR Annual Report, Table 11.9.
Figure 22: Unadjusted 1- and 5-year graft and patient survival
of heart transplants by recipient age.
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Figure 23: Prevalence of pediatric recipients living with a
functioning transplant at end of year, 1995–2004.
transplanted in the most recent era. Data from the PHTS
demonstrate that urgency status at listing is not predictive
of posttransplant survival, nor is the requirement for a ven-
tricular assist device as bridge to transplant (29,32). For
survivors of pediatric heart transplantation (approximately
2300 pediatric recipients in the United States at the end
of 2004) (Figure 23), the principal challenges involve pre-
vention of graft vasculopathy (6), prevention and treatment
of infection and malignancy (most notably PTLD) (33), and
minimization of end-organ toxicities secondary to immuno-
suppressive medications. Perhaps of greatest concern in
the latter category is the decline in renal function seen late
after heart transplantation with current calcineurin inhibitor-
based regimens (34,35). Increasing numbers of children
will require kidney transplantation over the next decade fol-
lowing extrarenal solid organ transplantation in childhood.
Finally, strategies to improve adherence to therapy are also
key to long-term survival, since adolescent nonadherence
appears to be a principal cause of death among teenagers
and young adults after heart transplantation (12,36).
Heart-Lung Transplantation
Heart-lung transplantation continues to be a relatively rare
procedure. The reasons are likely multifactorial and may
include current use of bilateral lung transplantation as the
procedure of choice for children with parenchymal lung
disease as well as most cases of primary pulmonary hy-
pertension. The relatively high death rate on the waiting
list (perhaps related to an inherent bias in the allocation
system against heart-lung transplants) and poor long-term
survival following transplantation may also discourage re-
ferral for consideration of transplantation.
Waiting list
During the past 10 years, the number of new heart-lung
registrants of all ages has been steadily decreasing. In
2004, there were only 78 new registrations nationwide
across all age groups. This has resulted in a gradual decline
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in the number of patients on the waiting list. In children,
the number of new registrants and active waiting list candi-
dates has always been extremely low. At the end of 2004,
only 25 children were on the heart-lung waiting list (active
and inactive); 15 of these 25 (60%) were in the 11–17-year
age group.
Transplantation and survival
Transplantation: The total number of heart-lung trans-
plants performed each year in the United States is very
small and has gradually declined over the last decade. In
2004, only 39 procedures were performed across all age
groups. During the past 5 years, the annual number of pe-
diatric heart-lung transplants performed has ranged from
five to eight per year, representing 15–22% of all heart-
lung transplants. In 2004, there were only six procedures
in children nationwide.
Survival: Data available on long-term pediatric heart-
lung graft and patient survival are limited; it is difficult to an-
alyze outcomes for so rare a procedure. Survival analyses
within the OPTN/SRTR Annual Report reflect transplants
performed over a small number of years only. While this
suffices for a description of survival for almost all other or-
gans across all age groups, it does not allow for appropriate
description of patient and graft survival for pediatric heart-
lung recipients. The registry of the International Society for
Heart and Lung Transplantation provides data on a larger co-
hort of pediatric recipients transplanted over a long period
of time. For the period 1982–2002, probability of survival
at 1 and 5 years after heart-lung transplantation in children
is approximately 65% and 40%, respectively (37). Lack of
improvement in survival over the last two decades is of
particular concern. The short-term results are somewhat
inferior to those of isolated lung transplantation, but the
long-term outcomes are comparable to those for bilateral
lung transplantation. This likely reflects the fact that the
lung allograft is the primary determinant of long-term sur-
vival after heart-lung transplantation and that obliterative
bronchiolitis (chronic rejection) and its complications are
the leading cause of death late after both lung and heart-
lung transplantation.
Lung Transplantation
As in previous years, the population of pediatric patients un-
dergoing lung transplantation remains quite different than
that of adults. In 2004, 36 of 54 (67%) pediatric lung trans-
plants were for cystic fibrosis (CF), compared with 178
of 1118 (16%) in adults. CF accounted for 5 of 10 (50%)
patients receiving lung transplants between the ages of
1 and 10 years and 31 of 40 (78%) patients aged 11–
17 years (SRTR analysis, August 2005). These percentages
are similar to those seen in international reports (27,37).
Lung transplant in the infant and toddler population con-
tinues to be an infrequent occurrence (five transplants in
2004). Although these patients carry diagnoses seen in
adults, such as alveolar proteinosis and interstitial lung dis-
ease, genetic studies of these infants have revealed etiolo-
gies distinct from adults including disorders of surfactant
protein B and C and the ABCA3 transporter (38–41). Other
indications for transplant unique to infancy include irrepara-
ble congenital cardiac or pulmonary vascular abnormalities
and pulmonary hypertension/hypoplasia associated with
congenital diaphragmatic hernia. Given that pediatric lung
transplants make up less than 5% of the total lung trans-
plant population, these differences make extrapolation of
models for waiting list mortality and posttransplant survival
from adults to children challenging. These models are in-
creasingly important components of allocation policy, as
well as benchmarks for evaluation of transplant center out-
comes. Therefore, careful consideration will continue to be
necessary when applying these models to pediatric candi-
dates.
Waiting list
In comparison with 2003 and reversing a trend over the
prior 2 years, the total number of active pediatric lung
transplant candidates increased (Figure 24). This change
resulted primarily from increased numbers in the groups
of patients 1–5 and 6–10 years of age (from 2 to 15
and 20 to 25, respectively). It is unclear whether this re-
flects a shift in referral patterns; there have been no ma-
jor changes in therapy for CF or pulmonary hypertension
during the past year. Moreover, the percentage of active
pediatric candidates among all active lung transplant can-
didates has increased from 5% in 2003 to 7% in 2004.
In addition, this also reflects a rather sharp decline in the
percentage of active adult candidates (Figure 25). This
disparity should continue in the coming year, as the virtual
elimination of waiting time from the lung allocation system
for patients 12 years and older (implemented in May 2005)
will likely lead to a sharp decline in the percentage of ac-
tive patients in the 12 years and older age group (reflecting
listing practice changes similar to those seen in liver trans-
plantation following implementation of MELD/PELD). The
percentage of active patients in the 11 year and under age
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Figure 24: Pediatric patients listed for lung transplant, dying
on the waiting list and transplanted, 1995–2004.



























Source: 2005 OPTN/SRTR Annual Report, Tables 12.1a and 12.1b and 2004 
OPTN/SRTR Annual Report, Table 12.1.
Figure 25: Percentage of patients listed for lung transplant
with active status, 1995–2004.
groups is unlikely to change because allocation remains
based on waiting time for this age group.
Determining median values for time to lung transplant is
not possible for the majority of age groups in the past
5 years because more than half of the patients in these
groups have yet to be transplanted. This likely reflects
the practice of listing patients early in order to accumu-
late enough waiting time to be offered organs when their
disease progresses. Based on the 10th and 25th per-
centile data, median waiting times will be at least 3–
4 months for patients less than 5 years of age, and at least
1–2 years for patients 6 years and older.
Although waiting list mortality in the pediatric population
historically has been above the mean, and the number of
waiting list deaths compared with transplants has generally
been high for pediatric candidates compared with adults
(Figure 26), in the past 2 years this trend shows some ev-
idence of reversing. This is reflected in decreases in total
waiting list deaths (Figure 24) as well as waiting list mor-
tality which, in 2004, for the 6–10 year and 11–17-year age
groups, was below the mean at 103 and 108 deaths per
1000 patient-years at risk, respectively. These are the low-
est values among any age group and among the lowest val-
ues for these pediatric age groups over the past 10 years.
Although interpretation of these data must be tempered
by the small number of patients they are based on, the im-
proved death rate observed for adolescent lung transplant
candidates is encouraging. In light of the large percentage
of CF patients in the adolescent age group and the unpre-
dictability of the course of this disease, we hope that the
adolescent preference incorporated into the modifications
to the lung allocation policy adopted in May 2005 will allow
this trend to continue.
Transplantation and survival
Transplantation: In 2003, there were 54 pediatric lung
transplants (both deceased and living donor). This repre-















Source: 2005 OPTN/SRTR Annual Report, Tables 12.3, 12.4a and 12.4b.
Figure 26: Ratio of waiting list deaths to transplants, pediatric
and adult, 1995–2004.
crease slightly since 2002 (Figure 24). These numbers still
represent a decline over the past decade from peaks of 67
transplants and 8% of all transplants in 1995. Given that the
waiting list for pediatric lung candidates (both active and to-
tal) has nearly doubled over the past 10 years, the factors
contributing to this decline most likely include decreasing
numbers of pediatric donors coupled with steady increases
in the number of adults listed for lung transplant. Living
donor lobar lung transplants (LDLLT) continued to make
up a very small percentage of transplants in 2004, repre-
senting less than 2% of total transplants. CF remained,
by far, the most common diagnosis in patients receiving
LDLLT. Two LDLLT recipients in 2004 had received a prior
lung transplant; there were three pediatric LDLLT recipi-
ents compared with five in 2003. This is probably not an
important difference, though over the decade, there appear
to be fewer LDLLT being done in both children and adults.
In addition to the relatively few programs willing to tackle
the technical and ethical complexities of a LDLLT program,
this decline may be due in part to recent data from the
University of Southern California program suggesting that
short- and long-term survival may be lower than that of de-
ceased donor recipients (42). However, promising results
from the program at Okayama University in Japan balance
this concern (43).
There were no major differences in the incidence of lung
transplantation in all pediatric age groups in comparison
with 2003. In general, the incidence of pediatric lung
transplant is less than half that in adults. Granting the
small numbers, the only pediatric age groups with sub-
stantial change in the past decade have been infants less
than 1-year old and children aged 1–5 years. Both have
declined by more than 50% from peak values. The reasons
for and import of this observation are unclear.
Survival: Patients with a history of prior transplant, on
mechanical support or hospitalized in an intensive care unit
continued to have the highest annual death rates per 1000
patient-years at risk. However, as a whole, death rates
in deceased donor recipients, including all pediatric age
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groups, have continued to decrease between 1995 and
2003, including a 31% decline over the past 2 years. For
pediatric recipients transplanted in 2003, only two deaths
occurred in the 11–17-year age group, yielding a rate of
74. This is the lowest value in the past decade, though the
numbers are quite variable. Although there are likely to be
multiple contributing factors, two relevant trends are no-
table; decreased induction use of T-cell directed antibodies
in favor of IL-2 receptor antagonists, perhaps leading to a
lower risk for early infection and a reduced death rate in pa-
tients with long ischemic times, perhaps a result of lower
incidence or severity of early graft dysfunction. These two
trends may be important because infection and early graft
dysfunction are the two most common causes of death in
the first year following transplantation (37).
The annual death rate in the first year after LDLLT also has
been comparable to that for deceased donor transplants for
the past 2 years after several years of being consistently
higher. Death rates in pediatric LDLLT recipients over the
past decade have been comparable to those of adults.
Although better than intestinal transplantation, long-term
survival after lung transplantation across all age groups re-
mains poor compared with heart, liver and kidney trans-
plantation. Unadjusted 5-year graft survival is 48% com-
pared with 69%, 67%, 72% and 32% for deceased donor
kidney, liver, heart and intestine transplant recipients, re-
spectively.
Subgroup analysis of lung transplant recipients again
showed that previous lung transplantation was a strong
predictor of poor graft survival. Although the numbers are
small, comparison of different age groups revealed the fol-
lowing: (1) Infants less than 1 year of age have worse early
unadjusted survival than other age groups, but comparable
5-year survival. (2) At 5 years, all pediatric age groups have
unadjusted survival comparable to adults (Figure 27). Sim-
ilar to previous observations (10,11), in the cohorts used
for this analysis, 5-year outcomes in adolescents appear
to be worse than in other children or adults younger than
65 years. Five-year unadjusted graft survival in all LDLLT
recipients is 41% compared with 48% in deceased donor
recipients. Unadjusted graft survival of pediatric LDLLT re-
cipients aged 6–10 years is 55% comparable to 50% in
adult LDLLT recipients aged 18–34 years.
An increasing percentage of pediatric lung transplants are
being performed in transplant programs that predominantly
serve adults (Figure 28). In the past 4 years, this has com-
prised roughly 40% of pediatric transplants and 20% of
transplants in recipients younger than 11 years. In contrast
to the growth of pediatric transplant programs overall, this
likely reflects that the number of active pediatric lung trans-
plant programs has not increased during the past decade
(Figure 29). Finally, only 5% of programs perform more
than 10 pediatric lung transplants per year. Lack of program
growth, coupled with small numbers of experienced pro-
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Figure 27: Unadjusted graft survival at 3 and 5 years for de-
ceased donor lung transplant recipients, by age.
grams, makes learning from experience and prospective
studies a considerable challenge. Nonetheless, lung trans-
plantation remains a viable therapy for end-stage pediatric
pulmonary parenchymal and pulmonary vascular disease
in pediatric patients, with outcomes comparable to those
seen in adults. Bronchiolitis obliterans and other late com-
plications remain as barriers to the long-term success of
pediatric lung transplantation. We look forward to the de-
velopment of multicenter collaborations and basic science
partnerships that take advantage of emerging technologies
such as gene array technology, molecular genomics and
proteomics in order to dissect the basic processes required
to prevent chronic graft dysfunction and lead to robust tol-
erance.
Allocation Policy Update
This section summarizes the pediatric-specific aspects of
organ allocation. Changes during the past year involved
preferentially directing organs from pediatric and younger
donors to pediatric candidates.
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Figure 28: Distribution of lung transplant recipients between
centers serving primarily pediatric or adult recipients for re-
cipients aged 0–17 years.
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Figure 29: Number of active pediatric transplant centers (re-
porting 1 or more transplant per year).
Kidney
To minimize the harmful developmental effects of end-
stage kidney failure, kidney allocation policy previously
gave pediatric candidates maximum priority after exceed-
ing preset waiting time goals. Despite this added advan-
tage, many children were not being transplanted quickly
after exceeding their time goals. Moreover, this policy also
created inefficiencies in the allocation system because a
significant percentage of kidneys offered under the policy
were being turned down because of donor age or organ
quality.
New kidney allocation policies: To address these con-
cerns, the policy of allocating kidneys to pediatric candi-
dates was revised so that kidneys from donors less than
35 years old are now offered preferentially to pediatric can-
didates. Only patients with 0 HLA mismatches and those
who are highly sensitized have higher priority. Pediatric can-
didates less than 11 years old are given additional point pri-
ority because of their younger age and the greater impact
of kidney failure on development.
Analyses presented to the OPTN Board of Directors
showed that this change will have a minimal impact on the
allocation system. Many pediatric recipients were already
receiving organs from donors less than 35 years old and
the total number (381) of pediatric recipients of deceased
donor kidneys is small compared with the 2595 deceased
kidney donors under 35 years of age in 2004.
Liver
Three major changes were made in organ allocation poli-
cies for pediatric liver candidates.
New liver policies: In 2004, approximately 37% of pe-
diatric liver recipients were transplanted at Status 1. The
previous pediatric Status 1 criteria were broad and included
variables that were subject to interpretation. This, coupled
with the ‘Status 1 by exception’ category, resulted in a large
percentage of pediatric candidates being listed at Status 1.
The revised Status 1 criteria are much more stringent, re-
move ‘Status 1 by exception’, and subdivide Status 1 into
two categories, 1A and 1B, that reflect different risks of
waiting list mortality (Table 2).
To address any potentially harmful consequence of the
new, more stringent Status 1 criteria, allocation of pe-
diatric livers was also revised to further favor pedi-
atric candidates. Previously, only pediatric candidates at
>50% risk of 3-month waiting list mortality (correspond-
ing to a PELD score >46) would be offered a pediatric
donor liver before any adult with a MELD score >30
(the 50% risk of 3-month waiting list mortality for adult
candidates).
The new pediatric preference algorithm shares pediatric
donor livers regionally to pediatric candidates based on
a PELD/MELD score rather than on a waiting list mor-
tality risk. After Status 1 patients are offered the pedi-
atric donor liver, the liver will be offered regionally to pe-
diatric candidates aged 0–11 years, then locally to pedi-
atric candidates aged 12–17 years with a MELD score
≥15, before being offered locally to adult candidates with a
MELD score ≥15. The revised algorithm is intended to pro-
mote broader sharing of pediatric donor livers to pediatric
candidates (especially to the youngest ones) and to en-
courage the splitting of young, healthy livers from adoles-
cent donors. Simulation modeling for this revised algorithm
also showed an increase in pediatric transplants adequate
enough to offset the anticipated decrease in pediatric trans-
plants from an earlier policy, where adult donor livers are
shared regionally at a MELD score >15 (SRTR analysis, July
2004).
The other policy change during the past year involved listing
pediatric candidates 12–17 years old using MELD scores.
MELD was felt to be a better predictor of mortality than
PELD because PELD does not consider the effect of kidney
failure.
Lung
Details of allocation policy for lung transplant patients can
be found elsewhere in this report (44). Most important,
pediatric donor lungs are now offered preferentially to
pediatric candidates before being offered to adult candi-
dates. Pediatric candidates 0–11 years old are assigned
priority based on waiting time, whereas pediatric can-
didates older than 12 years are assigned a lung alloca-
tion score. Lungs from donors 0–11 years old will be of-
fered first to pediatric candidates 0–11 years old, then
to candidates 12–17 years old, before being offered to
adult candidates. Lungs from donors 12–17 years old will
be first offered to candidates 12–17 years old, then to
candidates 0–11 years old, before being offered to adult
candidates.
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Table 2: Allocation criteria for pediatric liver candidates
Pediatric Status 1A criteria
Fulminant hepatic failure Onset of hepatic encephalopathy within 8 weeks of first symptoms of liver disease




Primary nonfunction Diagnosis within 7 days of transplantation
Must include two of the following
(1) ALT ≥2000
(2) INR >2.5
(3) Total bilirubin ≥10 mg/dL
(4) Acidosis, defined as pH ≤7.3 and/or lactate ≥2× normal
Hepatic artery thrombosis Diagnosis within 14 days of implantation
Acute decompensated Wilson’s disease
Pediatric Status 1B criteria
Chronic liver disease In the ICU
Calculated PELD or MELD >25
One of the following criteria are met
(1) On a mechanical ventilator
(2) GI bleeding requiring at least 30 cc/kg of RBC replacement with past 24 h
(3) Renal failure requiring hemodialysis/hemofiltration
(4) Glasgow coma score <10
Metabolic disease, Hepatoblastoma Pediatric candidates with urea cycle disorders or organic academias or hepatoblastomas
may receive a PELD/MELD score of 30. If candidate has not been transplanted within
30 days, then may be listed as Status 1B
Source: OPTN (24).
Heart
There have been no changes to the national system for
allocating deceased donor hearts. Candidates continue to
be assigned priority based upon medical urgency, blood
type, and waiting time. Pediatric candidates are assigned
medical urgency status codes based on criteria that take
into account differences in diseases, therapies and severity
of illness among pediatric candidates. They also receive
preference ahead of adult candidates in the allocation of
adolescent (i.e., 11–17 years old) donor hearts within each
medical urgency status.
Organ allocation policy includes pediatric-specific aspects
to preferentially direct pediatric donor organs to pediatric
candidates. The above revisions should yield better out-
comes and more efficient allocation of organs to pediatric
candidates. Details of the actual allocation policies can be
found at the OPTN web site (24).
Further Challenges in the Pediatric
Transplant Population
The data presented above support the conclusion that pedi-
atric organ transplantation has achieved levels of success,
in terms of both graft and patient survival that are com-
parable overall to adults. The overarching success of pe-
diatric transplantation is well represented by the pediatric
recipients alive at the end of 2004 (Figure 23). Nonethe-
less, three important themes—resulting in part because of
this success—warrant further consideration: organ avail-
ability, adolescent survival and challenges facing clinical
research.
The discussion above suggests that pediatric organ trans-
plant candidates will continue to face increasing competi-
tion from adults. This, coupled with decreasing numbers
of pediatric donors, will diminish access for pediatric can-
didates, particularly for those organs with donor size con-
straints. Organ donation initiatives and favorable allocation
policies will not completely mitigate this problem. One area
drawing increased attention is DCD. A recent SRTR anal-
ysis showed that, in 2004, there were 391 instances of
DCD, of which 41 donors were younger than 18 years of
age (10% of total DCD events). In 2004, there were 530
kidney transplants using DCD organs, six of which were re-
ceived by pediatric candidates. During the same time, 177
liver transplants were performed with DCD livers, three
of which involved a pediatric recipient (SRTR analysis, Au-
gust 2005). Expanded use of DCD organs is an exciting
possibility. However, the observed substantial increase in
delayed graft function (Table 3) associated with DCD in
kidney recipients must be assessed carefully before DCD
organs are routinely accepted for use in children.
A second focus is the perennial concern about adoles-
cent graft and patient survival. Although commonly as-
cribed to nonadherence, prospective validations of this
assumption—in spite of anecdotal experiences com-
mon to all centers—are difficult to obtain (45). Other
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Table 3: Donation after cardiac death, 1995–2004: incidence of delayed graft function
Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
No. of delayed graft function
Total 1884 1990 1874 1980 1974 1885 1964 1943 2028 2144
DCD 52 45 54 44 64 68 101 106 164 226
ECD (not DCD) 371 428 393 456 406 356 406 429 455 411
SCD 1461 1517 1427 1480 1504 1461 1457 1408 1409 1507
No. of Transplants
Total 7599 7595 7636 7893 7914 7958 8065 8287 8388 9025
DCD 103 94 117 105 142 163 246 287 393 530
ECD (not DCD) 990 1061 1123 1207 1209 1160 1165 1216 1315 1341
SCD 6506 6440 6396 6581 6563 6635 6654 6784 6680 7154
% Delayed graft function
Total 24.8% 26.2% 24.5% 25.1% 24.9% 23.7% 24.4% 23.4% 24.2% 23.8%
DCD 50.5% 47.9% 46.2% 41.9% 45.1% 41.7% 41.1% 36.9% 41.7% 42.6%
ECD (not DCD) 37.5% 40.3% 35.0% 37.8% 33.6% 30.7% 34.8% 35.3% 34.6% 30.6%
SCD 22.5% 23.6% 22.3% 22.5% 22.9% 22.0% 21.9% 20.8% 21.1% 21.1%
Source: SRTR Analysis, May 2005.
Note: DCD = donation after cardiac death, ECD = expanded criteria donor and SCD = standard criteria donor.
unexplored factors include the impact of adolescent de-
velopment on the pharmacodynamics and efficacy of im-
munosuppressant medications, the effect of adolescence
on the immune response and the effect of transitions be-
tween pediatric and adult caregivers. Although the transi-
tion of pediatric transplant recipients from pediatric trans-
plant centers to adult transplant centers is an area of
current focus (American Society of Transplantation adoles-
cent transition conference, Chicago, 2005), another unex-
plored transition is that which occurs when pediatric candi-
dates cared for by pediatric subspecialists undergo trans-
plant and receive posttransplant care from a center pri-
marily caring for adults. Review of OPTN data indicates
that more than 60% of recipients 11–17 years old receive
transplants in centers that transplant more adults than chil-
dren (OPTN data, 2005). It is difficult to determine from the
data set whether such centers have a different spectrum of
caregivers compared with pediatric centers. However, this
observation invites exploration of the pediatric services
available in all centers, particularly relating to adolescent
development and monitoring/prevention of nonadherence.
Indeed, the Pediatric and Membership committees of the
OPTN recently have discussed including specific criteria for
programs serving pediatric candidates as part of an overall
review of the OPTN requirements for transplant programs.
The final challenge facing pediatric transplantation re-
lates to clinical research. Although research cooperatives
(NAPRTCS, SPLIT, PHTS, IPLTC and the intestinal trans-
plant registry) have been successful to varying degrees in
reporting results of retrospective analyses, with the ex-
ception of NAPRTCS and the CCTPT, these groups have
been less successful in implementing prospective trials.
It is worth emphasizing that only 24% of centers perform-
ing pediatric transplants of any organ performed more than
10 total pediatric transplants in 2004. Furthermore, 42% of
pediatric transplants were performed in centers transplant-
ing more adults than children (OPTN data, 2005). Given
these observations, one must consider whether the major-
ity of pediatric transplants occur in places where pediatric
transplantation is not a research priority. The importance
of prospective studies is underscored by an observation
resulting from a CCTPT-sponsored steroid withdrawal trial
showing that the incidence of PTLD was increased (46). It
is unlikely that single-center studies would have made this
important observation. To ensure that we learn as much
from each pediatric transplant recipient as possible, the
pediatric transplant community must overcome the collab-
orative barriers of such a fragmented population.
Summary
Overall, the prospects for solid organ transplantation in chil-
dren, especially those aged 1–10 years, are excellent. Or-
gan allocation policies typically grant preference to these
patients, and long-term graft survival rates for this age
group are often equivalent to or exceed the outcomes of
transplantation in adults. Adolescents also receive prefer-
ence in allocation and have excellent short-term survival
in general. However, long-term outcomes in adolescents
continue to be suboptimal. Infants also remain a challeng-
ing population, with higher waiting list mortality and poorer
outcomes. However, evidence that long-term complica-
tions in infants may be lower (6,47), raises the question
whether outcomes for these patients could be improved
by shortening time to transplant.
The success of pediatric transplantation is in part responsi-
ble for the ongoing challenges the pediatric transplant com-
munity now faces. Larger waiting lists require considera-
tion of other sources of organs, such as DCD. Successful
1150 American Journal of Transplantation 2006; 6 (Part 2): 1132–1152
Pediatric Transplantation, 1995–2004
transplantation of adolescents requires more effective
management of their transition to adult caregivers. Finally,
although overall pediatric outcomes are now comparable
to those of adults, more effective collaborations for clinical
research are necessary to keep pace with improvements
in the adult world.
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